[{"id": 1199197, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199198, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199199, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199200, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199201, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199202, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199203, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199204, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199205, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199206, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199207, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199208, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199209, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199210, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199211, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199212, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199213, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199214, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199215, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199216, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199217, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199218, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "No recommendation", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199219, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199220, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199221, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199222, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199223, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199224, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199225, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199226, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199227, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199228, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199239, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199229, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Strong", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199230, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199231, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199232, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199233, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199234, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199235, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199236, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199237, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199238, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199240, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199241, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "n/a", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "No recommendation", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199242, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "n/a", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199243, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199244, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199245, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199252, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199246, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199247, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199248, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199249, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199250, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199251, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199253, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199254, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199255, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199256, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199257, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199258, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199259, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199260, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199261, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199262, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199263, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199264, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199265, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Moderate", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199266, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199267, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199268, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199269, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199322, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199270, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199271, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199272, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199273, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199274, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199275, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199340, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199276, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199277, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199278, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199279, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199280, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199281, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199282, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199283, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199284, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199285, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199286, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199287, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199288, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199289, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199290, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199291, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199292, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199311, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199293, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199294, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199295, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199296, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199297, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199298, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199341, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199299, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199300, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199301, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199302, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199303, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199304, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199305, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199306, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199307, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199308, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199309, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199310, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199312, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199313, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199314, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199315, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199316, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199317, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199318, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199319, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199320, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199321, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199388, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199323, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199324, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199325, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199326, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199327, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199328, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199329, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199330, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199331, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199332, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199333, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199334, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199335, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199336, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199337, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199338, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199339, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199342, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199343, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199344, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199345, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199346, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199347, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199348, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199349, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199350, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199351, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199352, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199353, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199354, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199355, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199356, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "No recommendation", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199357, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199389, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199358, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199359, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199360, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199361, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199362, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199363, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199364, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199365, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199366, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199367, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199368, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199369, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199370, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199371, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199372, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199373, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199374, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199375, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199376, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199377, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199378, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199379, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199390, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199380, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Moderate", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199381, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199382, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199383, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199384, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199385, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199386, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199387, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199391, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199392, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199393, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199394, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199395, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199396, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199397, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199398, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199399, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199400, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199401, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199402, "guidelineid": 100414, "drugid": "RxNorm:704", "implications": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "amitriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199550, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199551, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199552, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199553, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199554, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199555, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199556, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199557, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199558, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199559, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199560, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199561, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199562, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199563, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199564, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199565, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199566, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199567, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199568, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199569, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199588, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199570, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199571, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199572, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199573, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199574, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199575, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199589, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199576, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199577, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199578, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199579, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199580, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199613, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199581, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199582, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199583, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199584, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199585, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199586, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199587, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199614, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199590, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199591, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199592, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199593, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199594, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199595, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199596, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199597, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199598, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199615, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199599, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199600, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199601, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199602, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199603, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199604, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199616, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199605, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199606, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199607, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199608, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199609, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199610, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199611, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199612, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199617, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199618, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199619, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199620, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199621, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199622, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199623, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199624, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199625, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199626, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199627, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199628, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199629, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199630, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199631, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199632, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199633, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199634, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199635, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199636, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199637, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199638, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199639, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199640, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199641, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199642, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199643, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199644, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199645, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199646, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199647, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199648, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199649, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199650, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199651, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199652, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199653, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199654, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199655, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199656, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199657, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199658, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199659, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199660, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199661, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199662, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199663, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199664, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199695, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199665, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199666, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199667, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199668, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199669, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199670, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199671, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199672, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199673, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199674, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199675, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199676, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199677, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199678, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199679, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199680, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199681, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199682, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199683, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199684, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199685, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199686, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199687, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199688, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199689, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199690, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199691, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199692, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199693, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199694, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199696, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199697, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199698, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199699, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199700, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199701, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199702, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199703, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199704, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199705, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199706, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199707, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199708, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199709, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199710, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199711, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199712, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199713, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199714, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199715, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199716, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199717, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199718, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199719, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199720, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199721, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199722, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199723, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199724, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199725, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199726, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199727, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199728, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199729, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199730, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199731, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199732, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199733, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199734, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199735, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199736, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199737, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199738, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199739, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "No recommendation", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199740, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "n/a", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199741, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199742, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199743, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199744, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199745, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "No recommendation", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199746, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199747, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199748, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199749, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "n/a", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199750, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199751, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199752, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199753, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199754, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199755, "guidelineid": 100414, "drugid": "RxNorm:2597", "implications": {"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "clomipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199811, "guidelineid": 100414, "drugid": "RxNorm:3247", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "desipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199812, "guidelineid": 100414, "drugid": "RxNorm:3247", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "desipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199882, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199813, "guidelineid": 100414, "drugid": "RxNorm:3247", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "desipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199814, "guidelineid": 100414, "drugid": "RxNorm:3247", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "4.0"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "desipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199907, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199807, "guidelineid": 100414, "drugid": "RxNorm:3247", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22656"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "desipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199808, "guidelineid": 100414, "drugid": "RxNorm:3247", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22655"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "desipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199809, "guidelineid": 100414, "drugid": "RxNorm:3247", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "desipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199810, "guidelineid": 100414, "drugid": "RxNorm:3247", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "desipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199815, "guidelineid": 100414, "drugid": "RxNorm:3247", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "3.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "desipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199816, "guidelineid": 100414, "drugid": "RxNorm:3247", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "3.0"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "desipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199817, "guidelineid": 100414, "drugid": "RxNorm:3247", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "2.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "desipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199818, "guidelineid": 100414, "drugid": "RxNorm:3247", "implications": {"CYP2D6": "Normal metabolism of TCAs"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "2.25"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "desipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199819, "guidelineid": 100414, "drugid": "RxNorm:3247", "implications": {"CYP2D6": "Normal metabolism of TCAs"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "2.0"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "desipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199820, "guidelineid": 100414, "drugid": "RxNorm:3247", "implications": {"CYP2D6": "Normal metabolism of TCAs"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.75"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "desipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199821, "guidelineid": 100414, "drugid": "RxNorm:3247", "implications": {"CYP2D6": "Normal metabolism of TCAs"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "desipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199822, "guidelineid": 100414, "drugid": "RxNorm:3247", "implications": {"CYP2D6": "Normal metabolism of TCAs"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.25"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "desipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199823, "guidelineid": 100414, "drugid": "RxNorm:3247", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.0"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "desipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199824, "guidelineid": 100414, "drugid": "RxNorm:3247", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.75"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "desipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199825, "guidelineid": 100414, "drugid": "RxNorm:3247", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "desipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199826, "guidelineid": 100414, "drugid": "RxNorm:3247", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.25"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "desipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199827, "guidelineid": 100414, "drugid": "RxNorm:3247", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."}, "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.0"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "desipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199828, "guidelineid": 100414, "drugid": "RxNorm:3247", "implications": {"CYP2D6": "n/a"}, "drugrecommendation": "No recommendation", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Indeterminate"}, "activityscore": {"CYP2D6": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "desipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199843, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199837, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199838, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199839, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199840, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199841, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199842, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199844, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199845, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199846, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199847, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199848, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199849, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199850, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199851, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199852, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199853, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199916, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199854, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199855, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199856, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199857, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199858, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199859, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199860, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199861, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199862, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199863, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199864, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199870, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199865, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199866, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199867, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199868, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199869, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199871, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199872, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199873, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199874, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199875, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199876, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199877, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199878, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199879, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199880, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199881, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199883, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199884, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199885, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199886, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199887, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199888, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199917, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199889, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199890, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199891, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199892, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199893, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199894, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199931, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199895, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199896, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199897, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199898, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199899, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199900, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199901, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199902, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199903, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199904, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199905, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199906, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199908, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199909, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199910, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199911, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199912, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199913, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199914, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199915, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199918, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199919, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199920, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199921, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199922, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199923, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199924, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199925, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199926, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199927, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199928, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199929, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199930, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199932, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199933, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199934, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199935, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199936, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199937, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199938, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199939, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199940, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199941, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199942, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199943, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199944, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199945, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199946, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199947, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199948, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199949, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199988, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199950, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199951, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199952, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199953, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199954, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199955, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199956, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199957, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199958, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199959, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199960, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199961, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199962, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199963, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199964, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199965, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199966, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199967, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199968, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199969, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199970, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199971, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199972, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199973, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199974, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199975, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199976, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199977, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199978, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199979, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199980, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199981, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199982, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199983, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199984, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199985, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199986, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199987, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199989, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199990, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199991, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199992, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199993, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199994, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199995, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199996, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200109, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199997, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199998, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1199999, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200000, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200001, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200002, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200003, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200016, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200004, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200005, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200006, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200007, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200008, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200009, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200010, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200011, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200012, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200013, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200014, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200015, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200027, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "n/a", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200017, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200018, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200019, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200020, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200021, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200022, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200023, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200024, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200025, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200026, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "No recommendation", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200028, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200029, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200030, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200031, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200032, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "No recommendation", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200033, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200034, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200035, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200036, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "n/a", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200037, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200038, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200039, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200040, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200041, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200042, "guidelineid": 100414, "drugid": "RxNorm:3638", "implications": {"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "doxepin"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200103, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200104, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200105, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200106, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200107, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200108, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200110, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200111, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200112, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200113, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200114, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200115, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200116, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200117, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200118, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200119, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200120, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200121, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200122, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200123, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200124, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "No recommendation", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200125, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200126, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200137, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200127, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200128, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200129, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200130, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200131, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200132, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200133, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200134, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200135, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200136, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200138, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200139, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200140, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200141, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200142, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200143, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200144, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200145, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200146, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200147, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "n/a", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200148, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "n/a", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200249, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200149, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200150, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200151, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200152, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200153, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200154, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200155, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200156, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200157, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200158, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200159, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200250, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200160, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200161, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200162, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200163, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200164, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200165, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200166, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200167, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200168, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200169, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200170, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200171, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200172, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200173, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200174, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200175, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200176, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200228, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200177, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200178, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200179, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200180, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200181, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200182, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200229, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200183, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200184, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200185, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200186, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200187, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200188, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200189, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200190, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200191, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200192, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200193, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200194, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200195, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200196, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200197, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200198, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200199, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200230, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200200, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200201, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200202, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200203, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200204, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200205, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200247, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200206, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200207, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200208, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200209, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200210, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200211, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200212, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200213, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200214, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200215, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200216, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200217, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200218, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200219, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200220, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200221, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200222, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200223, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200224, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200225, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200226, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200227, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200231, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200232, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200233, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200234, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200235, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200236, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200237, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200238, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200239, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200240, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200248, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200241, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200242, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200243, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200244, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200245, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200246, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200251, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200252, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200253, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200254, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200255, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200256, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200257, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200258, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200259, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200260, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200261, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200262, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "No recommendation", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200263, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200264, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200265, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200299, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200266, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200267, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200268, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200269, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200270, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200271, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200272, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200273, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200274, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200275, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200276, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200277, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200278, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200279, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200280, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200281, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200282, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200283, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200284, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200285, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200286, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200287, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200288, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200289, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200290, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200291, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200292, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200293, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200294, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200295, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200296, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200297, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200298, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200300, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200301, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200302, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200303, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200304, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200305, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200306, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200307, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200308, "guidelineid": 100414, "drugid": "RxNorm:5691", "implications": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "imipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200356, "guidelineid": 100414, "drugid": "RxNorm:7531", "implications": {"CYP2D6": "Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "nortriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200352, "guidelineid": 100414, "drugid": "RxNorm:7531", "implications": {"CYP2D6": "Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22656"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "nortriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200353, "guidelineid": 100414, "drugid": "RxNorm:7531", "implications": {"CYP2D6": "Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22655"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "nortriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200354, "guidelineid": 100414, "drugid": "RxNorm:7531", "implications": {"CYP2D6": "Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "nortriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200355, "guidelineid": 100414, "drugid": "RxNorm:7531", "implications": {"CYP2D6": "Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "nortriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200357, "guidelineid": 100414, "drugid": "RxNorm:7531", "implications": {"CYP2D6": "Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "nortriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200358, "guidelineid": 100414, "drugid": "RxNorm:7531", "implications": {"CYP2D6": "Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "nortriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200359, "guidelineid": 100414, "drugid": "RxNorm:7531", "implications": {"CYP2D6": "Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "4.0"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "nortriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200360, "guidelineid": 100414, "drugid": "RxNorm:7531", "implications": {"CYP2D6": "Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "3.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "nortriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200361, "guidelineid": 100414, "drugid": "RxNorm:7531", "implications": {"CYP2D6": "Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "3.0"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "nortriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200362, "guidelineid": 100414, "drugid": "RxNorm:7531", "implications": {"CYP2D6": "Increased metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure."}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Strong", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "2.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "nortriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200363, "guidelineid": 100414, "drugid": "RxNorm:7531", "implications": {"CYP2D6": "Normal metabolism of tricyclic antidepressants"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "2.25"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "nortriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200364, "guidelineid": 100414, "drugid": "RxNorm:7531", "implications": {"CYP2D6": "Normal metabolism of tricyclic antidepressants"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "2.0"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "nortriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200365, "guidelineid": 100414, "drugid": "RxNorm:7531", "implications": {"CYP2D6": "Normal metabolism of tricyclic antidepressants"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.75"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "nortriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200366, "guidelineid": 100414, "drugid": "RxNorm:7531", "implications": {"CYP2D6": "Normal metabolism of tricyclic antidepressants"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "nortriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200367, "guidelineid": 100414, "drugid": "RxNorm:7531", "implications": {"CYP2D6": "Normal metabolism of tricyclic antidepressants"}, "drugrecommendation": "Initiate therapy with recommended starting dose", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.25"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "nortriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200368, "guidelineid": 100414, "drugid": "RxNorm:7531", "implications": {"CYP2D6": "Reduced metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.0"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of tricyclic antidepressants for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "nortriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200369, "guidelineid": 100414, "drugid": "RxNorm:7531", "implications": {"CYP2D6": "Reduced metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.75"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of tricyclic antidepressants for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "nortriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200370, "guidelineid": 100414, "drugid": "RxNorm:7531", "implications": {"CYP2D6": "Reduced metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.5"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of tricyclic antidepressants for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "nortriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200371, "guidelineid": 100414, "drugid": "RxNorm:7531", "implications": {"CYP2D6": "Reduced metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Moderate", "phenotypes": {"CYP2D6": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.25"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of tricyclic antidepressants for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "nortriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200372, "guidelineid": 100414, "drugid": "RxNorm:7531", "implications": {"CYP2D6": "Greatly reduced metabolism of tricyclic antidepressants to less active compounds compared to normal metabolizers. Higher plasma concentrations of active drug will increase the probability of side effects."}, "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider a 50% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Strong", "phenotypes": {"CYP2D6": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.0"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of tricyclic antidepressants for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "nortriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200373, "guidelineid": 100414, "drugid": "RxNorm:7531", "implications": {"CYP2D6": "n/a"}, "drugrecommendation": "No recommendation", "classification": "No Recommendation", "phenotypes": {"CYP2D6": "Indeterminate"}, "activityscore": {"CYP2D6": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a"}, "population": "general", "comments": "Because CYP2D6 phenotype could not be assigned based on genotyping performed, therapuetic monitoring should be considered. If therapuetic monitoring cannot be performed, monitor closely for toxicity and/or efficacy.", "version": 1, "drug": {"name": "nortriptyline"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200663, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200664, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200665, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200666, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200701, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200667, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200668, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200669, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200670, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200671, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200672, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200673, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200674, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200675, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200676, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200677, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200678, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200679, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200680, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200681, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200682, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200702, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200683, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200684, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200685, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200686, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200687, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200688, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200703, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200689, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200690, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200691, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200692, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200693, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200694, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200695, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "0.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.25", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200696, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "0.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.5", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200697, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "0.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0.75", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200698, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "1.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200699, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200700, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200704, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200705, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200706, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200707, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200708, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200709, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200710, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200711, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200712, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200713, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200714, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200715, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200716, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200717, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200718, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200729, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200719, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200720, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200721, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200722, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200723, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200724, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200725, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200726, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200727, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200728, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200730, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200731, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200732, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200733, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200734, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200735, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200736, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200737, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200738, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200739, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "1.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.25", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200740, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "1.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.5", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200741, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "1.75", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "1.75", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200742, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "2.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200743, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "Normal Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "2.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.25", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200744, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use. If a trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200745, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid trimipramine use. If a trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200746, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200747, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200748, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200749, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200750, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use. If a trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200751, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200752, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Poor Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "0.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "0", "CYP2C19": "No Result"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200753, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200754, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200755, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200756, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200757, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200758, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200759, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200760, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200761, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200762, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200763, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200764, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200765, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200766, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200767, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200768, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200769, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200770, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200771, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200772, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200773, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200774, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200775, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200776, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200777, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200808, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200778, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200779, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200780, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200781, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200782, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200783, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200784, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200785, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200786, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200787, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200788, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200789, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200790, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200791, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200792, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200793, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200794, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200795, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200796, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200797, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200798, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200799, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200800, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200801, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200802, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200803, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200804, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200805, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200806, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200807, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200809, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200810, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200811, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200812, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200813, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200814, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200815, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200816, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200817, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200818, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200819, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200820, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200821, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200822, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200823, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200824, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200825, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200826, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200827, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200828, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200829, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200830, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200831, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200832, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200833, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200834, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200835, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200836, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200837, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200838, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200839, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200840, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200841, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "2.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "2.5", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200842, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "3.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200843, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "3.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "3.5", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200844, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "4.0", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "4", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200845, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22653", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200846, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22653.25", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.25", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200847, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22653.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22653.5", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200848, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22654", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200849, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22654.5", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22654.5", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200850, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22655", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22655", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200851, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}, "drugrecommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "\u22656", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "\u22656", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200852, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "No recommendation", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200853, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "n/a", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "No recommendation", "classification": "Strong", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200854, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200855, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200856, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200857, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200858, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "No recommendation", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200859, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200860, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Optional", "phenotypes": {"CYP2D6": "Indeterminate", "CYP2C19": "No Result"}, "activityscore": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "n/a", "CYP2C19": "No Result"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200861, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200862, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "n/a", "CYP2C19": "Normal metabolism of tertiary amines"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Strong", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Normal Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Normal Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200863, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Poor Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200864, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Rapid Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Rapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200865, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Ultrarapid Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Ultrarapid Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200866, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "n/a", "CYP2C19": "n/a"}, "drugrecommendation": "No recommendation", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Indeterminate"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Indeterminate"}, "population": "general", "comments": "n/a", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200867, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}, "drugrecommendation": "Initiate therapy with recommended starting dose.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Likely Intermediate Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Likely Intermediate Metabolizer"}, "population": "general", "comments": "Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}, {"id": 1200868, "guidelineid": 100414, "drugid": "RxNorm:10834", "implications": {"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}, "drugrecommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.", "classification": "Optional", "phenotypes": {"CYP2D6": "No Result", "CYP2C19": "Likely Poor Metabolizer"}, "activityscore": {"CYP2D6": "No result", "CYP2C19": "n/a"}, "allelestatus": {}, "lookupkey": {"CYP2D6": "No Result", "CYP2C19": "Likely Poor Metabolizer"}, "population": "general", "comments": "Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.", "version": 1, "drug": {"name": "trimipramine"}, "guideline": {"name": "CYP2D6, CYP2C19 and Tricyclic Antidepressants"}}]